Authors
Chekhonin E.S.
Pirogov National Medical and Surgical Center, Moscow
Abstract
Objective: to consider the relevance and new directions for the use of anti-VEGF drugs in the treatment of diabetic retinopathy.
Methods: Literature review was carried out using PubMed, Сochrane Library search engines, an analysis of literature sources on a given topic published up to 2022 was performed.
Abstract. Data is analyzed from recent studies designed to evaluate the use of anti-VEGF drugs in diabetic retinopathy with various conditions and with or without macular edema diabetes. Certain major promising directions are being invested in the field of anti-VEGF therapy.
Keywords: Anti-VEGF, diabetic retinopathy, diabetic macular edema.
References
1. Fajzrahmanov R.R., Voropaev V.Ju., Suhanova A.V., et. al. Antiangiogennaja terapija neovaskuljarnoj vozrastnoj makuljarnoj degeneracii. Vestnik oftal’mologii. 2021. T. 137. № 1. S. 83-93. (In Russ.).
2. Fajzrahmanov R.R., Bosov Je.D., Shishkin M.M., et. al. Sovremennye aspekty terapii submakuljarnyh krovoizlijanij na fone makuljarnoj degeneracii. Vestnik oftal’mologii. 2022. T. 138. № 2. S. 87-93. (In Russ.)
3. Bosov Je.D., Fajzrahmanov R.R., Karpov G.O., Kalinin M.E., et. al. Morfofunkcional’naja rezul’tativnost’ operativnogo lechenija subretinal’nyh gemorragij. Sovremennye tehnologii v oftal’mologii. 2022. № 1 (41). S. 23-27. (In Russ.)
4. Chehonin E.S., Fajzrahmanov R.R., Suhanova A.V., et. al. Anti-VEGF pri diabeticheskoj retinopatii. Vestnik oftal’mologii. 2021. T. 137. № 4. S. 136-142. (In Russ.)
5. Bosov Je.D., Fajzrahmanov R.R., Karpov G.O., et. al. Analiz pokazatelej setchatki posle maloinvazivnoj hirurgii submakuljarnyh krovoizlijanij. Rossijskij obshhenacional’nyj oftal’mologicheskij forum. 2022. T. 1. S. 116-119. (In Russ.)
6. Polonelli L, et al. Antibody Complementarity-Determining Regions (CDRs) Can Display Differential Antimicrobial, Antiviral and Antitumor Activities. PLoS One. 2008; 3:e2371. doi:10.1371/journal.pone.0002371
7. Gabrielli E, et al. Antibody Complementarity-Determining Regions (CDRs): A Bridge between Adaptive and Innate Immunity. PLoS One. 2009; 4: e8187. doi:10.1371/journal.pone.0008187
8. Bahrami B, Zhu M, Hong T, et al. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia. 2016;59:1594-1608
9. Busch C, Zur D, Fraser-Bell S, Lains I, Santos AR, Lupidi M et al (2018) Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol 55(8):789–796
10. Busch, C., Fraser-Bell, S., Iglicki, M. et al. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. Acta Diabetol 56, 1341–1350 (2019). https://doi.org/10.1007/s00592-019-01416-4
11. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904–1914
12. Iglicki M, Busch C, Zur D, Okada M, Mariussi M, Chhablani JK, et al. (2018) Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: The International Retina Group real-life 24-month multicenter study. The IRGREL-DEX study. Retina 39(1), pp. 44–51. https://doi.org/10.1097/IAE.00000 00000002196
13. Malcles A, Dot C, Voirin N, Agard E, Vie AL, Bellocq D et al (2017) Real-life study in diabetic macular edema treated with dexamethasone implant: the reldex study. Retina. 37(4):753–760
14. Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ et al (2016) Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I Data. Am J Ophthalmol 172:72–79
15. Sun JK, Jampol LM. The Diabetic Retinopathy Clinical Research Network (DRCR.net) and Its Contributions to the Treatment of Diabetic Retinopathy. Ophthalmic Res. 2019;62(4):225-230. doi: 10.1159/000502779. Epub 2019 Sep 25.
16. Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD, Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021 Sep 1;139(9): 946-955. doi: 10.1001/jamaophthalmol.2021.2809.
17. Maturi RK, Glassman AR, Josic K, Antoszyk AN, Blodi BA, Jampol LM, Marcus DM, Martin DF, Melia M, Salehi-Had H, Stockdale CR, Punjabi OS, Sun JK; DRCR Retina Network. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial. JAMA Ophthalmol. 2021 Jul 1;139(7):701-712. doi: 10.1001/jamaophthalmol.2021.0606.
18. Nanegrungsunk O, Bressler NM. Prevention of vision-threatening complications in diabetic retinopathy: two perspectives based on results from the DRCR Retina Network Protocol W and the Regeneron-sponsored PANORAMA. Curr Opin Ophthalmol. 2021 Nov 1;32(6):590-598. doi: 10.1097/ICU.0000000000000799.
